Group 1 - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives product ecosystem [1] - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1] - The biotechnology sector has become one of the hottest industries in the capital market, driven by technological innovation and global healthcare demand [1] Group 2 - Since the introduction of Chapter 18A in 2018, which allows unprofitable biotechnology companies to list in Hong Kong, 78 companies have successfully gone public, raising approximately 131.64 billion HKD [2] - The total market capitalization of these 18A companies has reached nearly 1.5 trillion HKD, covering key areas such as antibodies, small molecules, vaccines, and innovative medical devices [2] - Institutional investors' holdings in the top 30 Hong Kong-listed healthcare companies have increased from 13.3 billion USD in 2017 to 43 billion USD by June 30, 2025, with the biotechnology sector particularly favored [2] Group 3 - In the first half of 2025, the healthcare sector in Hong Kong completed 27 refinancing activities, raising a total of 3.9 billion USD, surpassing the total refinancing amounts for 2022, 2023, and 2024 [3] - The Hong Kong stock market has seen significant performance from healthcare stocks, especially 18A companies, with 27 out of 260 healthcare companies experiencing over 200% increase in stock prices this year [3] - Among the top 20 companies with the highest first-day stock price increases in the Hong Kong IPO market this year, 9 are healthcare companies, with 6 of them seeing increases over 100% [3]

Core Insights - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives ecosystem [1] - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1] - The biotechnology sector has become one of the hottest industries in the capital market, driven by technological innovation and global healthcare demand [1] Group 1: Market Development - Since the listing reform in 2018, the biotechnology and healthcare sectors have rapidly developed in Hong Kong, with over 260 companies listed, totaling a market capitalization of over HKD 4.8 trillion, up from approximately HKD 1.2 trillion at the end of 2018 [1] - The introduction of Chapter 18A in the listing rules allowed unprofitable biotechnology companies to list, marking a key turning point for the healthcare market [2] - As of October 13, 2023, 78 Chapter 18A companies have successfully listed, raising approximately HKD 131.64 billion, with a total market capitalization of nearly HKD 1.5 trillion [2] Group 2: Investment Trends - Institutional investors have significantly increased their holdings in the top 30 healthcare companies listed in Hong Kong, from USD 13.3 billion in 2017 to USD 43 billion by June 30, 2025 [2] - The biotechnology sector is particularly favored, with institutional investors holding 34% of the sector's market capitalization as of mid-2025 [2] - In the first half of 2025, 10 healthcare companies went public in Hong Kong, raising USD 2.1 billion, with an average first-day increase of 30.4%, making Hong Kong the leading market for healthcare IPO financing globally [2] Group 3: Performance of Healthcare Stocks - The refinancing activities in the healthcare sector have been robust, with 27 refinancing transactions completed in the first half of 2025, totaling USD 3.9 billion, surpassing the total refinancing amounts for 2022, 2023, and 2024 [3] - Among the 260 healthcare companies, 27 have seen their stock prices increase by over 200% this year, with most being Chapter 18A companies [3] - The performance of healthcare stocks in the IPO market has been notable, with 9 out of the top 20 companies by first-day gains being healthcare firms, and 6 of them achieving gains over 100% [4]

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2023, to enhance its derivatives ecosystem and provide investors with effective risk management tools in the rapidly growing biotechnology sector [1]. Group 1: Market Development - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of 30 major biotechnology, pharmaceutical, and medical device companies listed in Hong Kong [1]. - Since the listing reform in 2018, the biotechnology and healthcare sectors have become the fastest-growing industries in Hong Kong's capital market, with over 260 companies listed and a total market capitalization exceeding HKD 4.8 trillion, quadrupling from approximately HKD 1.2 trillion at the end of 2018 [1]. Group 2: 18A Companies - The introduction of Chapter 18A in the listing rules in 2018 allowed unprofitable biotechnology companies to list in Hong Kong, marking a significant turning point for the healthcare market [2]. - As of October 13, 2023, 78 18A companies have successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 131.64 billion and achieving a total market capitalization of nearly HKD 1.5 trillion, covering key areas such as antibodies, small molecules, vaccines, innovative medical devices, surgical robots, and cell therapies [2]. Group 3: Institutional Investment - The development of the healthcare sector in Hong Kong has been supported by a diverse group of investors, including international investment institutions, healthcare funds, and mainland Chinese capital [2]. - According to Refinitiv, the total holdings of institutional investors in the top 30 Hong Kong-listed healthcare companies increased from USD 13.3 billion in 2017 to USD 43 billion by June 30, 2025, with the biotechnology sector particularly favored, accounting for 34% of institutional holdings in the Hong Kong biotechnology sector as of mid-2025 [2]. Group 4: Financing Activities - The healthcare sector has seen active refinancing activities, with 27 refinancing transactions completed in the first half of 2025, totaling USD 3.9 billion, surpassing the total refinancing amounts for the years 2022, 2023, and 2024 [3]. - The Hong Kong stock market has witnessed significant stock price increases in the healthcare sector, especially among 18A companies, with 27 out of 260 healthcare companies experiencing price increases exceeding 200% year-to-date [3]. Group 5: IPO Performance - In the first half of 2025, 10 healthcare companies went public in Hong Kong, raising USD 2.1 billion, with an average first-day increase of 30.4%, making Hong Kong the market with the highest new healthcare stock financing globally [2]. - Among the top 20 companies with the highest first-day price increases, 9 were healthcare companies, with 6 of them seeing increases of over 100% [4].

Core Viewpoint - Hong Kong Stock Exchange (HKEX) shares have dropped over 3%, currently trading at HKD 419.8, with a trading volume of HKD 4.454 billion, amid escalating trade tensions impacting market sentiment [1] Market Sentiment and Trading Environment - The recent escalation in trade tensions has led to a decline in investor risk appetite, resulting in a valuation correction for Hong Kong stocks [1] - Huatai Securities indicates that the key to short-term trading direction lies in whether market sentiment has reached an extreme point, suggesting there is still room for further release in market sentiment indicators [1] - The evolution of trade friction issues is expected to have significant variance over the next one to two weeks, indicating that high volatility may persist [1] Upcoming Earnings and Forecasts - HKEX is set to announce its third-quarter results on November 5, with UBS predicting a year-on-year revenue and net profit growth of 43% and 53%, respectively, reaching HKD 7.7 billion and HKD 4.8 billion, marking new highs [1] - UBS's forecasts exceed general market expectations by 8% and 11% [1] - Given the current market atmosphere and increased participation from southbound capital, UBS has raised its average daily trading volume forecast for HKEX from 9% to 16% for 2025 to 2027, and adjusted its earnings per share forecast upward by 7% to 12%, setting a target price of HKD 485 with a "neutral" rating [1]

智通财经APP获悉，港交所(00388)再跌超3%，截至发稿，跌3%，报419.8港元，成交额44.54亿港元。 消息面上，上周五贸易战升级态势超出市场，投资者风险偏好下降带动港股估值回调。华泰证券表示， 短期操作方向判断的关键在于市场情绪是否已经较为极致，从资金面和港股情绪指标看还有进一步释放 空间，贸易摩擦问题未来一两周演进路径方差较大，高波动行情或仍将持续。 值得注意的是，港交所将于11月5日公布第三季度业绩。瑞银预测季度收入及纯利将同比增长43%及 53%，达到77亿及48亿元，再创新高。该行预测较市场普遍预期高出8%及11%。考虑到市场气氛情况及 南下资金参与度上升，瑞银将港交所2025至2027年日均成交额预测上调9%至16%，并将港交所每股盈 利预测上调7%至12%，目标价485港元，评级"中性"。 ...

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index futures to enhance its expanding derivatives ecosystem, with trading set to begin on November 28, 2025 [1] Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index [1] - This product aims to provide investors with precise risk management tools [1] - The futures will complement existing biotechnology-related products and flagship stock index derivatives offered by the Hong Kong Stock Exchange [1] Group 2: Market Performance - As of October 13, the Hang Seng Medical ETF (159892) has a scale exceeding 5.6 billion, significantly surpassing similar products and ranking first [1] - The secondary market trading remains active, indicating good liquidity [1] - The ETF is considered a quality tool for investing in the Hong Kong biotechnology sector [1]

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index futures on November 28, 2025, providing investors with precise risk management tools in a rapidly growing sector [1] Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong that are eligible for Stock Connect trading [1] - The introduction of this futures product aims to enhance investment channels in the biotechnology sector and provide effective hedging tools [1] Group 2: Market Context - The biotechnology industry is currently one of the hottest sectors in the capital markets, driven by technological innovation and global healthcare demand [1] - Since the listing reform in 2018, the biotechnology and healthcare sectors have become some of the fastest-growing industries in Hong Kong's capital market [1] Group 3: Market Statistics - There are currently over 260 biotechnology and healthcare companies listed on the Hong Kong Stock Exchange, with a total market capitalization exceeding HKD 4.8 trillion, which is four times the approximately HKD 1.2 trillion at the end of 2018 [1]

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures, set to begin trading on November 28, 2025, providing investors with precise risk management tools in the rapidly growing biotechnology sector [1] Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong that are eligible for Stock Connect trading [1] - The introduction of this futures product aims to enhance investment channels in the biotechnology industry and provide effective hedging tools [1] Group 2: Market Context - The biotechnology sector is currently one of the hottest industries in the capital markets, driven by technological innovation and significant global healthcare demand [1] - Since the listing reform in 2018, biotechnology and healthcare have become one of the fastest-growing sectors in the Hong Kong capital market, with over 260 biotechnology and healthcare companies listed, totaling a market capitalization of over HKD 4.8 trillion, which is four times the approximately HKD 1.2 trillion at the end of 2018 [1] Group 3: Strategic Goals - The launch of the Hang Seng Biotechnology Index Futures is expected to further solidify Hong Kong's position as a leading center for derivative trading and risk management in Asia [1] - The Hong Kong Stock Exchange will continue to promote market development, increase market depth, and diversify product offerings to meet the evolving needs of global investors [1]

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index Futures to enhance its derivatives product ecosystem, focusing on the rapidly growing biotechnology sector [1] Group 1: Product Launch Details - The new futures contract will start trading on November 28, 2025, based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong that are eligible for Stock Connect trading [1] - The product aims to provide investors with precise risk management tools and complement existing biotechnology-related products and flagship stock index derivatives offered by the Hong Kong Stock Exchange [1] Group 2: Incentives and Fees - The first six months of trading for the new product will be exempt from the Securities and Futures Commission transaction fees [1] - The margin rate for the product will be announced in due course [1]

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com 格隆汇10月14日｜香港交易所宣布，计划推出恒生生物科技指数，进一步优化其不断拓展的衍生产品生 态圈。新合约将于2025年11月28日开始交易，合约以恒生生物科技指数为基准，聚焦当前发展最快、最 有活力的一大板块，为投资者提供精准的风险管理工具，并与香港交易所现有的生物科技相关产品及旗 舰股票指数衍生产品组合互补。 ...